Life Science Leader Magazine Supplements

CMO 2015

The vision of Life Science Leader is to help facilitate connections and foster collaborations in pharma and med device development to get more life-saving and life-improving therapies to market in an efficient manner. Connect, Collaborate, Contribute

Issue link:

Contents of this Issue


Page 15 of 83

LIFESCIENCELEADER.COM THE CMO LEADERSHIP AWARDS 2015 16 Passion for your Process, Product and Patients Contract manufacturing of biologics is more than having superior technology – it's having experienced people who are passionate, responsive and committed to developing and manufacturing your biotherapeutics to improve patient care. We invite you to feel the difference at Therapure Biomanufacturing, where the client experience is our passion and patient care is our commitment. Please visit us at Or contact: Dina Iezzi Director, Marketing & Special Projects Phone: +1 (905) 286-6270 Mobile: +1 (647) 234-3395 Email: Therapure Biomanufacturing, a division of Therapure Biopharma Inc. ©2015 Therapure Biopharma Inc. All rights reserved. Development Services Cell Line; Upstream; Downstream; Analytical cGMP Manufacturing Upstream Production; Downstream Purification Aseptic Fill/Finish Vials; Syringes; Lyophilization ROUNDTABLE leaders When a company is looking for capital funding, how should it prepare, and what should executives bring with them to that meeting? CHRIS ACHAR, Genzum Life Sciences: When talking to outside investors for the first time, I think having a well-vetted busi- ness model is the most important part. Given how competitive the start-up world is today, investors have a lot of options to invest in. For yours to stand out, having that solid business model is everything. TIBA AYNECHI, Novo Ventures: When people come to us with an early stage opportunity, what's important for us is for people to have a good handle on how much they're raising and what meaning- ful milestones they hope to achieve. You need to have a well-thought-out plan, and you need to make sure your plan is reflec- tive of the data you have in hand. We don't like to invest in speculative data. It's important for companies to work backwards. Figure out what the exit sce- nario is going to be, and when it is likely to occur. Your finances need to be able to take you to that point. You have to think very nuanced and detailed about the proj- ect, and not in general terms. We want somebody who thinks in detail and not generalized themes. Do companies generally come in well prepared? AYNECHI: I think it's 50/50. Most people assume it will be a smooth ride, but it's not, and it inevitably takes longer than you think. You really need to think about contingencies and various scenarios if things don't go according to plan. We also like to focus on the manage- ment team. Is this something the team has done before, or is it their first time? As an investor, we are investing in that team. If we have an experienced team, they can always regroup quickly. KEVIN JUDICE, DiCE Molecules: I think the idea of starting at the end and working backwards is really important. Think about how much capital you need to get to the point where investors can get a multiple of that capital back. Take into account that what you're doing is a science-based endeavor. That means there is going to be a lot of back and forth. Always ask yourself if anyone will be willing to pay money for it. At what phase would they buy it? How much money will it take to get this to that phase? This is a for-profit business, and our investors would like to get back a multiple of the money they give you. If you are looking for funding, you need to sit down and think about that. What happens when someone comes in and they are not prepared? Are you able to help them? JULIE PAPANEK, Canaan Partners: If someone FINDING INVESTORS AND CAPITAL TO MATCH YOUR GOALS By E. Miseta

Articles in this issue

Links on this page

Archives of this issue

view archives of Life Science Leader Magazine Supplements - CMO 2015